JP2024039317A - Composition for film coating, solid preparation, and method for producing solid preparation - Google Patents
Composition for film coating, solid preparation, and method for producing solid preparation Download PDFInfo
- Publication number
- JP2024039317A JP2024039317A JP2022143774A JP2022143774A JP2024039317A JP 2024039317 A JP2024039317 A JP 2024039317A JP 2022143774 A JP2022143774 A JP 2022143774A JP 2022143774 A JP2022143774 A JP 2022143774A JP 2024039317 A JP2024039317 A JP 2024039317A
- Authority
- JP
- Japan
- Prior art keywords
- film coating
- examples
- pullulan
- coating composition
- mass
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 239000007888 film coating Substances 0.000 title claims abstract description 59
- 238000009501 film coating Methods 0.000 title claims abstract description 59
- 238000002360 preparation method Methods 0.000 title claims description 28
- 239000007787 solid Substances 0.000 title claims description 27
- 238000004519 manufacturing process Methods 0.000 title claims description 12
- 238000000576 coating method Methods 0.000 claims abstract description 48
- 229920001218 Pullulan Polymers 0.000 claims abstract description 46
- 239000004373 Pullulan Substances 0.000 claims abstract description 46
- 235000019423 pullulan Nutrition 0.000 claims abstract description 46
- 229920003086 cellulose ether Polymers 0.000 claims abstract description 43
- 239000002904 solvent Substances 0.000 claims abstract description 27
- 239000007864 aqueous solution Substances 0.000 claims abstract description 15
- 239000011248 coating agent Substances 0.000 claims description 44
- 239000004480 active ingredient Substances 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 10
- 150000005846 sugar alcohols Chemical class 0.000 claims description 8
- 229920013820 alkyl cellulose Polymers 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 239000007921 spray Substances 0.000 abstract description 11
- 239000000243 solution Substances 0.000 abstract description 9
- 230000001877 deodorizing effect Effects 0.000 abstract description 8
- 238000007788 roughening Methods 0.000 abstract description 3
- 238000010586 diagram Methods 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 31
- -1 hydroxypropoxy groups Chemical group 0.000 description 22
- 235000001014 amino acid Nutrition 0.000 description 17
- 229940024606 amino acid Drugs 0.000 description 17
- 239000000654 additive Substances 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 13
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 13
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 235000019645 odor Nutrition 0.000 description 8
- 230000003746 surface roughness Effects 0.000 description 8
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 150000008163 sugars Chemical class 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000007941 film coated tablet Substances 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 5
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 5
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 229920000609 methyl cellulose Polymers 0.000 description 5
- 235000010981 methylcellulose Nutrition 0.000 description 5
- 239000001923 methylcellulose Substances 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 239000011247 coating layer Substances 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- WLDHEUZGFKACJH-UHFFFAOYSA-K amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1N=NC1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-UHFFFAOYSA-K 0.000 description 3
- 239000002221 antipyretic Substances 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000021466 carotenoid Nutrition 0.000 description 3
- 150000001747 carotenoids Chemical class 0.000 description 3
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- JFVXEJADITYJHK-UHFFFAOYSA-L disodium 2-(3-hydroxy-5-sulfonato-1H-indol-2-yl)-3-oxoindole-5-sulfonate Chemical compound [Na+].[Na+].Oc1c([nH]c2ccc(cc12)S([O-])(=O)=O)C1=Nc2ccc(cc2C1=O)S([O-])(=O)=O JFVXEJADITYJHK-UHFFFAOYSA-L 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 229960003511 macrogol Drugs 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000009495 sugar coating Methods 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- OALHHIHQOFIMEF-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 OALHHIHQOFIMEF-UHFFFAOYSA-N 0.000 description 2
- DBTMGCOVALSLOR-UHFFFAOYSA-N 32-alpha-galactosyl-3-alpha-galactosyl-galactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(C(CO)OC(O)C2O)O)OC(CO)C1O DBTMGCOVALSLOR-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RXVWSYJTUUKTEA-UHFFFAOYSA-N D-maltotriose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 RXVWSYJTUUKTEA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000002744 anti-aggregatory effect Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000002518 antifoaming agent Substances 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000003430 antimalarial agent Substances 0.000 description 2
- 239000003434 antitussive agent Substances 0.000 description 2
- 229940124584 antitussives Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- 239000003576 central nervous system agent Substances 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 229960003624 creatine Drugs 0.000 description 2
- 239000006046 creatine Substances 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 229940066493 expectorants Drugs 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- 229960000991 ketoprofen Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000004089 psychotropic agent Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000007940 sugar coated tablet Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 2
- SWGJCIMEBVHMTA-UHFFFAOYSA-K trisodium;6-oxido-4-sulfo-5-[(4-sulfonatonaphthalen-1-yl)diazenyl]naphthalene-2-sulfonate Chemical compound [Na+].[Na+].[Na+].C1=CC=C2C(N=NC3=C4C(=CC(=CC4=CC=C3O)S([O-])(=O)=O)S([O-])(=O)=O)=CC=C(S([O-])(=O)=O)C2=C1 SWGJCIMEBVHMTA-UHFFFAOYSA-K 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- FYGDTMLNYKFZSV-BYLHFPJWSA-N β-1,4-galactotrioside Chemical group O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-BYLHFPJWSA-N 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- JJVXHDTWVIPRBZ-VKHMYHEASA-N (2r)-2-[carboxy(methyl)amino]-3-sulfanylpropanoic acid Chemical compound OC(=O)N(C)[C@@H](CS)C(O)=O JJVXHDTWVIPRBZ-VKHMYHEASA-N 0.000 description 1
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
- KYBXNPIASYUWLN-WUCPZUCCSA-N (2s)-5-hydroxypyrrolidine-2-carboxylic acid Chemical compound OC1CC[C@@H](C(O)=O)N1 KYBXNPIASYUWLN-WUCPZUCCSA-N 0.000 description 1
- BAPRUDZDYCKSOQ-RITPCOANSA-N (2s,4r)-1-acetyl-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound CC(=O)N1C[C@H](O)C[C@H]1C(O)=O BAPRUDZDYCKSOQ-RITPCOANSA-N 0.000 description 1
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- 239000001096 (4-ethenyl-1-azabicyclo[2.2.2]octan-7-yl)-(6-methoxyquinolin-4-yl)methanol hydrochloride Substances 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- NNKXWRRDHYTHFP-HZQSTTLBSA-N (r)-[(2s,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;hydron;dichloride Chemical compound Cl.Cl.C([C@H]([C@H](C1)C=C)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 NNKXWRRDHYTHFP-HZQSTTLBSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- FEDJGPQLLNQAIY-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridazin-3-yl)oxy]acetic acid Chemical compound OC(=O)COC=1C=CC(=O)NN=1 FEDJGPQLLNQAIY-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000222518 Agaricus Species 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- AKJDEXBCRLOVTH-UHFFFAOYSA-N Carbetapentane citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C1(C(=O)OCCOCCN(CC)CC)CCCC1 AKJDEXBCRLOVTH-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 239000004212 Cryptoxanthin Substances 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FDJCVHVKXFIEPJ-JCNFZFLDSA-N Delapril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 FDJCVHVKXFIEPJ-JCNFZFLDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- KTNROWWHOBZQGK-UHFFFAOYSA-N Etilefrine hydrochloride (TN) Chemical compound [Cl-].CC[NH2+]CC(O)C1=CC=CC(O)=C1 KTNROWWHOBZQGK-UHFFFAOYSA-N 0.000 description 1
- RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- PNMUAGGSDZXTHX-BYPYZUCNSA-N Gly-Gln Chemical compound NCC(=O)N[C@H](C(O)=O)CCC(N)=O PNMUAGGSDZXTHX-BYPYZUCNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108010008488 Glycylglycine Proteins 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 235000001715 Lentinula edodes Nutrition 0.000 description 1
- 240000000759 Lepidium meyenii Species 0.000 description 1
- 235000000421 Lepidium meyenii Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- XZTYGFHCIAKPGJ-UHFFFAOYSA-N Meclofenoxate Chemical compound CN(C)CCOC(=O)COC1=CC=C(Cl)C=C1 XZTYGFHCIAKPGJ-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- KSMRODHGGIIXDV-YFKPBYRVSA-N N-acetyl-L-glutamine Chemical compound CC(=O)N[C@H](C(O)=O)CCC(N)=O KSMRODHGGIIXDV-YFKPBYRVSA-N 0.000 description 1
- CAHKINHBCWCHCF-UHFFFAOYSA-N N-acetyltyrosine Chemical compound CC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 CAHKINHBCWCHCF-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 241001482311 Trionychidae Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- DDNCQMVWWZOMLN-IRLDBZIGSA-N Vinpocetine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OCC)N5C2=C1 DDNCQMVWWZOMLN-IRLDBZIGSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- NTCYWJCEOILKNG-ROLPUNSJSA-N [(1r,2s)-1-hydroxy-1-phenylpropan-2-yl]-dimethylazanium;chloride Chemical compound Cl.CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 NTCYWJCEOILKNG-ROLPUNSJSA-N 0.000 description 1
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 description 1
- 229960005488 aceglutamide Drugs 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- JUGOREOARAHOCO-UHFFFAOYSA-M acetylcholine chloride Chemical compound [Cl-].CC(=O)OCC[N+](C)(C)C JUGOREOARAHOCO-UHFFFAOYSA-M 0.000 description 1
- 229960004266 acetylcholine chloride Drugs 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 239000011795 alpha-carotene Substances 0.000 description 1
- 235000003903 alpha-carotene Nutrition 0.000 description 1
- ANVAOWXLWRTKGA-HLLMEWEMSA-N alpha-carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)\C)(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C ANVAOWXLWRTKGA-HLLMEWEMSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960000852 alprenolol hydrochloride Drugs 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 229960003731 amlexanox Drugs 0.000 description 1
- SGRYPYWGNKJSDL-UHFFFAOYSA-N amlexanox Chemical compound NC1=C(C(O)=O)C=C2C(=O)C3=CC(C(C)C)=CC=C3OC2=N1 SGRYPYWGNKJSDL-UHFFFAOYSA-N 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 229940033495 antimalarials Drugs 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 229960002028 atropine sulfate Drugs 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 229960005412 bacampicillin hydrochloride Drugs 0.000 description 1
- IWVTXAGTHUECPN-ANBBSHPLSA-N bacampicillin hydrochloride Chemical compound [H+].[Cl-].C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OC(C)OC(=O)OCC)=CC=CC=C1 IWVTXAGTHUECPN-ANBBSHPLSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 235000002360 beta-cryptoxanthin Nutrition 0.000 description 1
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 229960000503 bisacodyl Drugs 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 229940067573 brown iron oxide Drugs 0.000 description 1
- 235000021329 brown rice Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 229940098391 carbetapentane citrate Drugs 0.000 description 1
- 239000006229 carbon black Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- CEZCCHQBSQPRMU-UHFFFAOYSA-L chembl174821 Chemical compound [Na+].[Na+].COC1=CC(S([O-])(=O)=O)=C(C)C=C1N=NC1=C(O)C=CC2=CC(S([O-])(=O)=O)=CC=C12 CEZCCHQBSQPRMU-UHFFFAOYSA-L 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 239000000470 constituent Chemical group 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 235000019244 cryptoxanthin Nutrition 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- PMKLVGOZGNPKLG-UHFFFAOYSA-H dialuminum;2',4',5',7'-tetraiodo-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate Chemical compound [Al+3].[Al+3].O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C([O-])C(I)=C1OC1=C(I)C([O-])=C(I)C=C21.O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C([O-])C(I)=C1OC1=C(I)C([O-])=C(I)C=C21.O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C([O-])C(I)=C1OC1=C(I)C([O-])=C(I)C=C21 PMKLVGOZGNPKLG-UHFFFAOYSA-H 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- 229960000920 dihydrocodeine Drugs 0.000 description 1
- HFBYLYCMISIEMM-FFHNEAJVSA-N dihydrocodeine phosphate Chemical compound OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC HFBYLYCMISIEMM-FFHNEAJVSA-N 0.000 description 1
- 229960005316 diltiazem hydrochloride Drugs 0.000 description 1
- 229960001056 dimemorfan Drugs 0.000 description 1
- KBEZZLAAKIIPFK-NJAFHUGGSA-N dimemorfan Chemical compound C1C2=CC=C(C)C=C2[C@@]23CCN(C)[C@@H]1[C@H]2CCCC3 KBEZZLAAKIIPFK-NJAFHUGGSA-N 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940073563 dl- methylephedrine hydrochloride Drugs 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- SBNKFTQSBPKMBZ-UHFFFAOYSA-N ethenzamide Chemical compound CCOC1=CC=CC=C1C(N)=O SBNKFTQSBPKMBZ-UHFFFAOYSA-N 0.000 description 1
- 229960000514 ethenzamide Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229960005172 etilefrine hydrochloride Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930002879 flavonoid pigment Natural products 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 229950006836 fursultiamine Drugs 0.000 description 1
- JTLXCMOFVBXEKD-FOWTUZBSSA-N fursultiamine Chemical compound C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N JTLXCMOFVBXEKD-FOWTUZBSSA-N 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940127227 gastrointestinal drug Drugs 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 108010010147 glycylglutamine Proteins 0.000 description 1
- 229940043257 glycylglycine Drugs 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 229960002146 guaifenesin Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 description 1
- 229960004135 idebenone Drugs 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000012902 lepidium meyenii Nutrition 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- SXQCTESRRZBPHJ-UHFFFAOYSA-M lissamine rhodamine Chemical compound [Na+].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O SXQCTESRRZBPHJ-UHFFFAOYSA-M 0.000 description 1
- 229960002983 loperamide hydrochloride Drugs 0.000 description 1
- PGYPOBZJRVSMDS-UHFFFAOYSA-N loperamide hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 PGYPOBZJRVSMDS-UHFFFAOYSA-N 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229960001637 meclofenoxate hydrochloride Drugs 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- CMUHZRATLMUDJI-UHFFFAOYSA-N methyl 2h-pyridine-1-carboxylate Chemical compound COC(=O)N1CC=CC=C1 CMUHZRATLMUDJI-UHFFFAOYSA-N 0.000 description 1
- 229940016409 methylsulfonylmethane Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 description 1
- 229960004027 molsidomine Drugs 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960002362 neostigmine Drugs 0.000 description 1
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 1
- KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 description 1
- 229960001454 nitrazepam Drugs 0.000 description 1
- 229960004708 noscapine Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- VWMVAQHMFFZQGD-UHFFFAOYSA-N p-Hydroxybenzyl acetone Natural products CC(=O)CC1=CC=C(O)C=C1 VWMVAQHMFFZQGD-UHFFFAOYSA-N 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940067631 phospholipid Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- JZQKKSLKJUAGIC-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CN2 JZQKKSLKJUAGIC-UHFFFAOYSA-N 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- FFNMBRCFFADNAO-UHFFFAOYSA-N pirenzepine hydrochloride Chemical compound [H+].[H+].[Cl-].[Cl-].C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 FFNMBRCFFADNAO-UHFFFAOYSA-N 0.000 description 1
- 229960000293 pirenzepine hydrochloride Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229960002244 promethazine hydrochloride Drugs 0.000 description 1
- XXPDBLUZJRXNNZ-UHFFFAOYSA-N promethazine hydrochloride Chemical compound Cl.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 XXPDBLUZJRXNNZ-UHFFFAOYSA-N 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 229960001811 quinine hydrochloride Drugs 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- NJGBTKGETPDVIK-UHFFFAOYSA-N raspberry ketone Chemical compound CC(=O)CCC1=CC=C(O)C=C1 NJGBTKGETPDVIK-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- AZJPTIGZZTZIDR-UHFFFAOYSA-L rose bengal Chemical compound [K+].[K+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 AZJPTIGZZTZIDR-UHFFFAOYSA-L 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 238000009496 sugar coating process Methods 0.000 description 1
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- 229960002780 talampicillin Drugs 0.000 description 1
- SOROUYSPFADXSN-SUWVAFIASA-N talampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(=O)OC2C3=CC=CC=C3C(=O)O2)(C)C)=CC=CC=C1 SOROUYSPFADXSN-SUWVAFIASA-N 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 229960000744 vinpocetine Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
【課題】防臭に十分な効果を示し、コーティング工程におけるスプレーノズルの閉塞が発生せず、錠剤同士の付着による錠剤表面の荒れがないフィルムコーティング用組成物の提供。【解決手段】20℃における2質量%水溶液の粘度が2.0~50.0mPa・sである非イオン性水溶性セルロースエーテル、プルラン及び溶媒を少なくとも含み、前記非イオン性水溶性セルロースエーテルとプルランとの質量比が80:20~55:45であるフィルムコーティング用組成物。【選択図】なしThe present invention provides a film coating composition that exhibits a sufficient deodorizing effect, does not cause clogging of spray nozzles in the coating process, and does not cause roughening of tablet surfaces due to adhesion of tablets to each other. [Solution] The present invention includes at least a nonionic water-soluble cellulose ether, pullulan, and a solvent whose viscosity of a 2% by mass aqueous solution at 20° C. is 2.0 to 50.0 mPa·s, the nonionic water-soluble cellulose ether and pullulan A film coating composition having a mass ratio of 80:20 to 55:45. [Selection diagram] None
Description
本発明は、錠剤等から発生する薬物由来の特有のにおいをマスキングするフィルムコーティング用組成物、これにより被覆された固形製剤及び固形製剤の製造方法に関する。 The present invention relates to a film coating composition for masking the characteristic drug-derived odor generated from tablets, etc., a solid preparation coated with the same, and a method for producing the solid preparation.
フィルムコーティングや糖衣は、経口固形製剤における、薬物の不快な味に対するマスキング、酸素の遮断、防湿又は製品としての美観の向上等の目的で広く行われている。
一方、薬物は、その活性成分自体や不純物や分解物に起因した臭気を有する場合がある。
Film coating and sugar coating are widely used in oral solid preparations for purposes such as masking unpleasant taste of drugs, blocking oxygen, moisture proofing, and improving the aesthetic appearance of the product.
On the other hand, drugs may have odors due to their active ingredients themselves, impurities, and decomposition products.
特に、活性成分に由来するにおいの隠蔽、酸素の遮断及び防湿を目的とした技術としては、例えば、糖衣コーティングやポリビニルアルコールと、ポリビニルアルコールに対して100質量%以上のタルクとを含有することにより、粘着性を低減して良好なフィルムコーティング性を得、かつ活性成分の臭気を充分に遮蔽でき、酸素遮蔽効果にも優れるフィルムコーティング組成物(特許文献1)が知られている。また、特許文献2では臭いを有する薬物を含有する固形製剤を防臭するためのフィルムコーティング組成物として、プルランおよび界面活性剤を含有するフィルムコーティング組成物が挙げられている。 In particular, techniques aimed at concealing odors derived from active ingredients, blocking oxygen, and moisture-proofing include, for example, sugar coating, polyvinyl alcohol, and talc containing 100% by mass or more based on the polyvinyl alcohol. A film coating composition (Patent Document 1) is known that can reduce tackiness and obtain good film coating properties, can sufficiently block the odor of the active ingredient, and has an excellent oxygen shielding effect. Further, Patent Document 2 cites a film coating composition containing pullulan and a surfactant as a film coating composition for deodorizing a solid preparation containing a drug having an odor.
しかしながら、糖衣コーティングは糖衣の作業工程に長時間を要し、製造コストの上昇や、製剤が服用困難な程大きくなること、コーティングに用いられるゼラチンの主成分であるタンパク質が変性してしまい安定性に欠けるという問題がある。
一方、特許文献1で挙げられているように無機物を多量に含有するフィルムコーティング組成物は、被膜が連続膜にならず、被膜強度に劣り、防臭性に劣る。また、特許文献2で挙げられる方法を用いると、粘着性はある程度低減されるものの完全ではなく、コーティングした錠剤表面は平滑にはならない。
However, sugar coating requires a long time for the sugar coating process, which increases manufacturing costs, makes the formulation so large that it is difficult to take, and the protein, which is the main component of gelatin used for coating, denatures and becomes unstable. There is a problem that there is a lack of
On the other hand, as mentioned in Patent Document 1, film coating compositions containing a large amount of inorganic substances do not form a continuous film, have poor film strength, and have poor odor resistance. Furthermore, when the method mentioned in Patent Document 2 is used, the tackiness is reduced to some extent, but not completely, and the coated tablet surface does not become smooth.
本発明は、上記事情に鑑みなされたもので、防臭に十分な効果を示し、コーティング工程におけるスプレーノズルの閉塞が発生せず、錠剤同士の付着による錠剤表面の荒れがないフィルムコーティング用組成物、これによりコーティングされた固形製剤、および固形製剤の製造方法を提供することを目的とする。 The present invention has been made in view of the above circumstances, and provides a film coating composition that exhibits sufficient deodorizing effects, does not cause clogging of spray nozzles during the coating process, and does not cause roughening of the tablet surface due to adhesion of tablets to each other. The object of the present invention is to provide a coated solid preparation and a method for producing the solid preparation.
本発明者らは、上記課題を解決するために鋭意研究を重ねた結果、非イオン性水溶性セルロースエーテル、プルラン及び溶媒を含み、かつ所定の比率で非イオン性水溶性セルロースエーテルとプルランとを少なくとも含むフィルムコーティング用組成物により、上記目的が達成されることを見出し、本発明を完成した。 As a result of extensive research to solve the above problems, the present inventors have discovered that the present invention contains nonionic water-soluble cellulose ether, pullulan, and a solvent, and that the nonionic water-soluble cellulose ether and pullulan are mixed in a predetermined ratio. The present invention was completed based on the discovery that the above object can be achieved by a film coating composition containing at least the following.
本発明によれば、以下のフィルムコーティング用組成物及び固形製剤並びに固形製剤の製造方法が提供される。
[1]20℃における2質量%水溶液の粘度が2.0~50.0mPa・sである非イオン性水溶性セルロースエーテル、プルラン及び溶媒を少なくとも含み、前記非イオン性水溶性セルロースエーテルとプルランとの質量比が80:20~55:45であるフィルムコーティング用組成物。
[2]非イオン性水溶性セルロースエーテルとプルランの総質量100質量部に対して、糖アルコール及び糖類の総含有量が30質量部以下である[1]に記載のフィルムコーティング用組成物。
[3]前記非イオン性水溶性セルロースエーテルがアルキルセルロース、ヒドロキシアルキルセルロース、及びヒドロキシアルキルアルキルセルロースからなる群から選ばれる[1]又は[2]に記載のフィルムコーティング用組成物。
[4]前記溶媒が、水及び炭素数1~3のアルコールからなる群から選ばれる[1]~[3]のいずれかに記載のフィルムコーティング用組成物。
[5]活性成分を少なくとも含む芯部と、前記芯部を[1]~[4]のいずれかに記載のフィルムコーティング用組成物により被覆した被覆部とを少なくとも含む固形製剤。
[6]活性成分を少なくとも含む芯部に、[1]~[4]のいずれかに記載のフィルムコーティング用組成物を被覆して被覆部を形成する工程と、乾燥して前記溶媒を除去する工程とを少なくとも含む固形製剤の製造方法。
According to the present invention, the following film coating composition, solid preparation, and method for producing the solid preparation are provided.
[1] At least contains a nonionic water-soluble cellulose ether, pullulan, and a solvent whose viscosity in a 2% by mass aqueous solution at 20°C is 2.0 to 50.0 mPa·s, and the nonionic water-soluble cellulose ether and pullulan A film coating composition having a mass ratio of 80:20 to 55:45.
[2] The film coating composition according to [1], wherein the total content of sugar alcohol and saccharide is 30 parts by mass or less based on 100 parts by mass of the nonionic water-soluble cellulose ether and pullulan.
[3] The film coating composition according to [1] or [2], wherein the nonionic water-soluble cellulose ether is selected from the group consisting of alkyl cellulose, hydroxyalkyl cellulose, and hydroxyalkyl alkyl cellulose.
[4] The film coating composition according to any one of [1] to [3], wherein the solvent is selected from the group consisting of water and alcohols having 1 to 3 carbon atoms.
[5] A solid preparation comprising at least a core portion containing at least an active ingredient, and a coating portion in which the core portion is coated with the film coating composition according to any one of [1] to [4].
[6] A step of coating a core portion containing at least an active ingredient with the film coating composition according to any one of [1] to [4] to form a coated portion, and drying to remove the solvent. A method for producing a solid dosage form, comprising at least the steps of:
本発明によれば、防臭性に優れ、粘着性が改善された良好なフィルムコーティング性を有する経口投与に好適な固形製剤及びその製造方法並びに該固形製剤の製造に用いるフィルムコーティング用組成物を提供できる。 According to the present invention, there is provided a solid preparation suitable for oral administration that has excellent deodorization properties, improved adhesion, and good film coating properties, a method for producing the same, and a film coating composition used for producing the solid preparation. can.
1.フィルムコーティング用組成物
まず、20℃における2質量%水溶液の粘度が2.0~50.0mPa・sである非イオン性水溶性セルロースエーテル、プルラン及び溶媒を少なくとも含み、前記非イオン性水溶性セルロースエーテルとプルランとの質量比が80:20~55:45であるフィルムコーティング用組成物について説明する。
1. Film coating composition First, the composition comprises at least a nonionic water-soluble cellulose ether, pullulan, and a solvent having a viscosity of 2.0 to 50.0 mPa·s in a 2% by mass aqueous solution at 20°C; A film coating composition in which the mass ratio of ether to pullulan is 80:20 to 55:45 will be described.
非イオン性水溶性セルロースエーテルは、セルロースの水酸基の一部をエーテル化した非イオン性の高分子である。非イオン性水溶性セルロースエーテルとしては、アルキルセルロース、ヒドロキシアルキルセルロース、ヒドロキシアルキルアルキルセルロース等が挙げられる。
アルキルセルロースとしては、メチルセルロース(以下、「MC」とも記載する)等が挙げられる。メチルセルロースにおけるメトキシ基の含有量は、好ましくは26.0~33.0質量%、より好ましくは27.5~31.5質量%である。メチルセルロースにおけるメトキシ基の含有量は、第十八改正日本薬局方のメチルセルロースに関する分析方法に準じて測定できる。
Nonionic water-soluble cellulose ether is a nonionic polymer obtained by etherifying some of the hydroxyl groups of cellulose. Examples of nonionic water-soluble cellulose ethers include alkylcellulose, hydroxyalkylcellulose, hydroxyalkylalkylcellulose, and the like.
Examples of the alkyl cellulose include methyl cellulose (hereinafter also referred to as "MC"). The content of methoxy groups in methylcellulose is preferably 26.0 to 33.0% by mass, more preferably 27.5 to 31.5% by mass. The content of methoxy groups in methylcellulose can be measured according to the analytical method for methylcellulose in the 18th edition of the Japanese Pharmacopoeia.
ヒドロキシアルキルセルロースとしては、ヒドロキシプロピルセルロース等が挙げられる。ヒドロキシプロピルセルロースにおけるヒドロキシプロポキシ基の含有量は、好ましくは53.4~80.5質量%、より好ましくは60.0~70.0質量%である。ヒドロキシプロピルセルロースにおけるヒドロキシプロポキシ基の含有量は、第十八改正日本薬局方のヒドロキシプロピルセルロースに関する分析方法に準じて測定できる。 Examples of hydroxyalkylcellulose include hydroxypropylcellulose. The content of hydroxypropoxy groups in hydroxypropylcellulose is preferably 53.4 to 80.5% by mass, more preferably 60.0 to 70.0% by mass. The content of hydroxypropoxy groups in hydroxypropylcellulose can be measured according to the analytical method for hydroxypropylcellulose in the 18th edition of the Japanese Pharmacopoeia.
ヒドロキシアルキルアルキルセルロースとしては、ヒドロキシプロピルメチルセルロース(別名「ヒプロメロース」、以下、「HPMC」とも記載する)等が挙げられる。HPMCにおけるメトキシ基の含有量は、良好なコーティング層(被膜、フィルム)を付与する観点から、好ましくは16.5~30.0質量%であり、より好ましくは28.0~30.0質量%である。また、HPMCにおけるヒドロキシプロポキシ基の含有量は、良好なコーティング層(被膜、フィルム)を付与する観点から、好ましくは4.0~32.0質量%であり、より好ましくは7.0~12.0質量%である。HPMCにおけるヒドロキシプロポキシ基及びメトキシ基の含有量は、第十八改正日本薬局方の「ヒプロメロース」の項に記載の定量法によって測定できる。 Examples of the hydroxyalkylalkylcellulose include hydroxypropylmethylcellulose (also known as "hypromellose", hereinafter also referred to as "HPMC"), and the like. The content of methoxy groups in HPMC is preferably 16.5 to 30.0% by mass, more preferably 28.0 to 30.0% by mass from the viewpoint of providing a good coating layer (film, film). It is. Further, the content of hydroxypropoxy groups in HPMC is preferably 4.0 to 32.0% by mass, more preferably 7.0 to 12.0% by mass, from the viewpoint of providing a good coating layer (film, film). It is 0% by mass. The content of hydroxypropoxy groups and methoxy groups in HPMC can be measured by the quantitative method described in the "hypromellose" section of the 18th edition of the Japanese Pharmacopoeia.
非イオン性水溶性セルロースエーテルとしては、良好なコーティング層(被膜、フィルム)を付与する観点から、メトキシ基の含有量が好ましくは16.5~30.0質量%であり、ヒドロキシプロポキシ基の含有量が好ましくは4.0~32.0質量%であるHPMCや、メトキシ基の含有量が好ましくは26.0~33.0質量%のメチルセルロースが好ましい。 From the viewpoint of providing a good coating layer (film, film), the nonionic water-soluble cellulose ether preferably has a methoxy group content of 16.5 to 30.0% by mass, and a hydroxypropoxy group content. HPMC having a content of preferably 4.0 to 32.0% by mass and methylcellulose having a methoxy group content of preferably 26.0 to 33.0% by mass are preferred.
非イオン性水溶性セルロースエーテルの20℃における2質量%水溶液の粘度は、2.0~50.0mPa・s、好ましくは2.0~25.0mPa・s、より好ましくは5.0~7.0mPa・sである。2.0mPa・s未満では、非イオン性水溶性セルロースエーテルの重合度が極端に低下するためコーティング層(被膜、フィルム)としての強度を保持できないおそれがある。一方、50.0mPa・sを超えると、非イオン性水溶性セルロースエーテルのフィルムコーティング用組成物における濃度を低く抑えなければならず、コーティング操作に長時間を有するため効率的な生産を行うことができない。非イオン性水溶性セルロースエーテルの20℃における2質量%水溶液の粘度は、第十八改正日本薬局方に記載の一般試験法の粘度測定方法の毛細管粘度計法に従い、ウベローデ型粘度計を用いて測定することができる。 The viscosity of a 2% by mass aqueous solution of nonionic water-soluble cellulose ether at 20°C is 2.0 to 50.0 mPa·s, preferably 2.0 to 25.0 mPa·s, more preferably 5.0 to 7.0 mPa·s. It is 0 mPa·s. If it is less than 2.0 mPa·s, the degree of polymerization of the nonionic water-soluble cellulose ether will be extremely reduced, so there is a possibility that the strength of the coating layer (film, film) cannot be maintained. On the other hand, if it exceeds 50.0 mPa・s, the concentration of nonionic water-soluble cellulose ether in the film coating composition must be kept low, and the coating operation takes a long time, making efficient production difficult. Can not. The viscosity of a 2% by mass aqueous solution of nonionic water-soluble cellulose ether at 20°C was determined using an Ubbelohde viscometer according to the capillary viscometer method of the viscosity measurement method of the general test method described in the 18th edition of the Japanese Pharmacopoeia. can be measured.
非イオン性水溶性セルロースエーテルは、必要に応じて2種類以上を併用してもよい。また、非イオン性水溶性セルロースエーテルは、市販のものを用いることができる。 Two or more types of nonionic water-soluble cellulose ethers may be used in combination, if necessary. Moreover, commercially available nonionic water-soluble cellulose ethers can be used.
プルランは、グルコースのみからなる多糖類の一種で、グルコースがα-1,4結合で3分子連なったマルトトリオースを構成単位とし、マルトトリオースがα-1,6結合を介して連結した構造を有する水溶性高分子多糖である。 Pullulan is a type of polysaccharide consisting only of glucose, and its constituent unit is maltotriose, in which three molecules of glucose are linked through α-1,4 bonds, and the maltotriose is linked through α-1,6 bonds. It is a water-soluble polymeric polysaccharide with
本発明に用いられるプルランとしては、平均分子量や分子量分布に特に制限はなく、市販の粉末状のプルランを用いることができる。 There are no particular limitations on the average molecular weight or molecular weight distribution of the pullulan used in the present invention, and commercially available powdered pullulan can be used.
フィルムコーティング用組成物中における非イオン性水溶性セルロースエーテルとプルランの質量比は、80:20~55:45であり、好ましくは80:20~60:40である。非イオン性水溶性セルロースエーテルが80超過であると、防臭に十分な効果を得ることができない。一方、プルランが45超過であると、被覆工程におけるスプレーノズルの閉塞及び錠剤の付着が発生し、被覆部表面が荒れてしまう。また、非イオン性水溶性セルロースエーテルが55未満であると、被覆工程におけるスプレーノズルの閉塞及び錠剤の付着が発生し、被覆部表面が荒れてしまう。一方、プルランが20未満であると、防臭に十分な効果を得ることができない。 The mass ratio of nonionic water-soluble cellulose ether to pullulan in the film coating composition is from 80:20 to 55:45, preferably from 80:20 to 60:40. If the nonionic water-soluble cellulose ether is more than 80, a sufficient deodorizing effect cannot be obtained. On the other hand, if the pullulan content exceeds 45, clogging of the spray nozzle and adhesion of tablets will occur during the coating process, and the surface of the coated portion will become rough. Moreover, if the nonionic water-soluble cellulose ether is less than 55, clogging of the spray nozzle and adhesion of the tablets will occur in the coating process, and the surface of the coated portion will become rough. On the other hand, if the pullulan content is less than 20, sufficient deodorizing effects cannot be obtained.
溶媒の例としては、水又は炭素数1~3のアルコール等が挙げられ、水と炭素数1~3のアルコールとの混合溶媒等であってもよい。水としては、精製水等が挙げられる。炭素数1~3のアルコールとしては、エタノール、メタノール、イソプロピルアルコール等が挙げられる。溶媒は、必要に応じて2種類以上を併用してもよい。溶媒としては、被覆時における生産性及び操作性の観点から、水が好ましい。 Examples of the solvent include water or an alcohol having 1 to 3 carbon atoms, and may also be a mixed solvent of water and an alcohol having 1 to 3 carbon atoms. Examples of water include purified water. Examples of the alcohol having 1 to 3 carbon atoms include ethanol, methanol, isopropyl alcohol, and the like. Two or more types of solvents may be used in combination as necessary. As the solvent, water is preferred from the viewpoint of productivity and operability during coating.
また、溶媒は、市販のものを用いることができる。フィルムコーティング用組成物における溶媒の含有量は、被覆時における操作性及び作業性の観点から、非イオン性水溶性セルロースエーテルとプルランの総質量100質量部に対して、好ましくは200~2000質量部、より好ましくは900~930質量部である。 Moreover, a commercially available solvent can be used. From the viewpoint of operability and workability during coating, the content of the solvent in the film coating composition is preferably 200 to 2000 parts by mass based on 100 parts by mass of the total mass of nonionic water-soluble cellulose ether and pullulan. , more preferably 900 to 930 parts by mass.
フィルムコーティング用組成物には、必要に応じて、添加剤を含めてもよい。添加剤の例としては、糖類及び糖アルコールが挙げられる。
糖類の例としては、ショ糖、ブドウ糖及び乳糖等の単糖類又は二糖類が挙げられる。なお、本明細書において「糖類」に非イオン性水溶性セルロースエーテル及びプルランは含まない。
糖アルコールの例としてはエリトリトール、キシリトール、ソルビトール、マンニトール及びマルチトールが挙げられる。
上記糖衣錠の問題点を改善するために、非イオン性水溶性セルロースエーテルとプルランの総質量100質量部に対して、糖アルコール及び糖類の総含有量は好ましくは30質量部以下、より好ましくは0~30質量部、更に好ましくは0~10質量部、特に好ましくは0~5質量部である。前記範囲のような少量の添加により、コーティング中の付着をより抑制でき、操作性が向上する利点がある。
The film coating composition may contain additives, if necessary. Examples of additives include sugars and sugar alcohols.
Examples of sugars include monosaccharides or disaccharides such as sucrose, glucose, and lactose. In addition, in this specification, "saccharide" does not include nonionic water-soluble cellulose ether and pullulan.
Examples of sugar alcohols include erythritol, xylitol, sorbitol, mannitol and maltitol.
In order to improve the above-mentioned problems of sugar-coated tablets, the total content of sugar alcohols and saccharides is preferably 30 parts by mass or less, more preferably 0 parts by mass, based on 100 parts by mass of nonionic water-soluble cellulose ether and pullulan. ~30 parts by weight, more preferably 0 to 10 parts by weight, particularly preferably 0 to 5 parts by weight. Addition of a small amount within the above range has the advantage of further suppressing adhesion during coating and improving operability.
また、フィルムコーティング用組成物には、更に必要に応じて、糖類及び糖アルコール以外の添加剤を含めてもよい。糖類及び糖アルコール以外の添加剤の例として、可塑剤、滑択剤、光沢化剤、界面活性剤、着色剤、可食性顔料、甘味料、コーティング剤及び消泡剤等が挙げられる。 Furthermore, the film coating composition may further contain additives other than sugars and sugar alcohols, if necessary. Examples of additives other than sugars and sugar alcohols include plasticizers, lubricants, brighteners, surfactants, colorants, edible pigments, sweeteners, coating agents, antifoaming agents, and the like.
可塑剤の例としては、グリセリン、ポリエチレングリコール、プロピレングリコール及びクエン酸トリエチル等が挙げられる。
滑沢剤の例としては、タルク、ステアリン酸マグネシウム、ステアリン酸カルシウム、コロイダルシリカ及びステアリン酸等が挙げられる。
光沢化剤の例としては、カルナウバロウ、シェラック、ミツロウ、硬化油及びステアリン酸マグネシウム等が挙げられる。
Examples of plasticizers include glycerin, polyethylene glycol, propylene glycol, triethyl citrate, and the like.
Examples of lubricants include talc, magnesium stearate, calcium stearate, colloidal silica, stearic acid, and the like.
Examples of brightening agents include carnauba wax, shellac, beeswax, hydrogenated oils, magnesium stearate, and the like.
界面活性剤の例としては、ポリソルベート80、ポリソルベート60、ショ糖脂肪酸エステル、マクロゴール400、ラウリル硫酸ナトリウム、ステアリン酸ポリオキシル40及びポリオキシエチレン硬化ヒマシ油60等が挙げられる。
着色剤の例としては、黄酸化鉄、三二酸化鉄(赤色)、オレンジエッセンス、褐色酸化鉄、カラメル、軽質無水ケイ酸、食用青色5号、食用黄色4号、食用黄色4号アルミニウムレーキ、食用黄色5号、食用赤色2号、食用赤色3号、食用赤色102号、食用青色2号、タルク、フルオレセインナトリウム、緑茶末、ビタミンC、食用レーキ色素、カロテノイド系色素、フラボノイド系色素及びキノン系色素等が挙げられる。
Examples of surfactants include polysorbate 80, polysorbate 60, sucrose fatty acid ester, macrogol 400, sodium lauryl sulfate, polyoxyl stearate 40, and polyoxyethylene hydrogenated castor oil 60.
Examples of colorants include yellow iron oxide, iron sesquioxide (red), orange essence, brown iron oxide, caramel, light silicic anhydride, food blue No. 5, food yellow No. 4, food yellow No. 4 aluminum lake, food Yellow No. 5, Food Red No. 2, Food Red No. 3, Food Red No. 102, Food Blue No. 2, talc, sodium fluorescein, green tea powder, vitamin C, food lake pigment, carotenoid pigment, flavonoid pigment, and quinone pigment. etc.
可食性顔料の例としては、カーボンブラック、食用赤色2号アルミニウムレーキ、食用赤色3号アルミニウムレーキ、食用赤色40号アルミニウムレーキ、食用黄色4号アルミニウムレーキ、食用黄色5号アルミニウムレーキ、食用青色1号アルミニウムレーキ、食用青色2号アルミニウムレーキ、三二酸化鉄、黄色三二酸化鉄及び黒酸化鉄等が挙げられる。
甘味料の例としては、アセスルファムカリウム、サッカリン、アスパルテーム及びスクラロース等が挙げられる。
コーティング剤としては、アラビアゴム、エチルセルロース、ヒドロキシプロピルセルロース、カルボキシビニルポリマー及びカルボキシメチルエチルセルロース等が挙げられる。
消泡剤の例としては、グリセリン脂肪酸エステル、ジメチルポリシロキサン、二酸化ケイ素混合物、ショ糖脂肪酸エステル等が挙げられる。
Examples of edible pigments include carbon black, Food Red No. 2 Aluminum Lake, Food Red No. 3 Aluminum Lake, Food Red No. 40 Aluminum Lake, Food Yellow No. 4 Aluminum Lake, Food Yellow No. 5 Aluminum Lake, Food Blue No. 1 Examples include aluminum lake, food blue No. 2 aluminum lake, iron sesquioxide, yellow iron sesquioxide, and black iron oxide.
Examples of sweeteners include acesulfame potassium, saccharin, aspartame, and sucralose.
Examples of the coating agent include gum arabic, ethylcellulose, hydroxypropylcellulose, carboxyvinyl polymer, and carboxymethylethylcellulose.
Examples of antifoaming agents include glycerin fatty acid esters, dimethylpolysiloxanes, silicon dioxide mixtures, sucrose fatty acid esters, and the like.
フィルムコーティング用組成物における糖類及び糖アルコール以外の添加剤の含有量は、非イオン性水溶性セルロースエーテルとプルランの総質量100質量部に対して、好ましくは30質量部以下、より好ましくは0~10質量部である。 The content of additives other than sugars and sugar alcohols in the film coating composition is preferably 30 parts by mass or less, more preferably 0 to 100 parts by mass, based on 100 parts by mass of the nonionic water-soluble cellulose ether and pullulan. It is 10 parts by mass.
フィルムコーティング用組成物は、20℃における2質量%水溶液の粘度が2.0~50.0mPa・sである非イオン性水溶性セルロースエーテル、プルラン及び溶媒と、必要に応じて添加剤を混合することにより、フィルムコーティング用組成物を得る工程により製造することができる。
20℃における2質量%水溶液の粘度が2.0~50.0mPa・sである非イオン性水溶性セルロースエーテル、プルラン及び溶媒と、必要に応じての添加剤の混合方法は、特に制限されない。例えば、非イオン性水溶性セルロースエーテルの「ままこ」の形成やゲル化を防ぐ観点から、フィルムコーティング用組成物を得る工程として、プルランと溶媒を混合することにより、プルラン溶液を得る工程と、前記プルラン溶液と非イオン性水溶性セルロースエーテルを混合する工程を少なくとも含むフィルムコーティング用組成物の製造方法が挙げられる。
The film coating composition is prepared by mixing nonionic water-soluble cellulose ether, pullulan, and a solvent whose viscosity in a 2% by mass aqueous solution at 20°C is 2.0 to 50.0 mPa·s, and optionally additives. By this, it can be manufactured by the process of obtaining a film coating composition.
There are no particular restrictions on the method of mixing the nonionic water-soluble cellulose ether, pullulan, and the solvent, whose viscosity in a 2% by mass aqueous solution at 20° C. is 2.0 to 50.0 mPa·s, and optional additives. For example, from the viewpoint of preventing the formation of "mamako" and gelation of nonionic water-soluble cellulose ether, the step of obtaining a film coating composition includes a step of obtaining a pullulan solution by mixing pullulan and a solvent; A method for producing a film coating composition includes at least a step of mixing the pullulan solution and a nonionic water-soluble cellulose ether.
プルランと溶媒を混合することにより、プルラン溶液を得る工程においては、20~30℃の溶媒にプルランを分散したのちに混合することにより、プルランを溶解して、プルラン溶液を得ることが好ましい。
また、前記プルラン溶液と非イオン性水溶性セルロースエーテルを混合することにより、フィルムコーティング用組成物を得る工程においては、好ましくは70~90℃の前記プルラン溶液に非イオン性水溶性セルロースエーテルを分散したのちに、好ましくは15~30℃まで冷却し、混合することにより、非イオン性水溶性セルロースエーテルを溶解して、フィルムコーティング用組成物を得ることが好ましい。
In the step of obtaining a pullulan solution by mixing pullulan and a solvent, it is preferable to disperse pullulan in a solvent at 20 to 30° C. and then mix to dissolve the pullulan and obtain a pullulan solution.
In addition, in the step of obtaining a film coating composition by mixing the pullulan solution and nonionic water-soluble cellulose ether, nonionic water-soluble cellulose ether is preferably dispersed in the pullulan solution at 70 to 90°C. Thereafter, the nonionic water-soluble cellulose ether is preferably dissolved by cooling to preferably 15 to 30° C. and mixing to obtain a film coating composition.
20℃における2質量%水溶液の粘度が2.0~50.0mPa・sである非イオン性水溶性セルロースエーテルと、プルランと、溶媒と、必要に応じての添加剤の混合は、撹拌機を用いて行うことができる。混合時間は、20℃における2質量%水溶液の粘度が2.0~50.0mPa・sである非イオン性水溶性セルロースエーテルと、プルランを溶媒に溶解させることができれば特に制限されない。 A stirrer is used to mix the nonionic water-soluble cellulose ether whose viscosity in a 2% by mass aqueous solution at 20°C is 2.0 to 50.0 mPa·s, pullulan, a solvent, and additives as necessary. It can be done using The mixing time is not particularly limited as long as the nonionic water-soluble cellulose ether whose viscosity of a 2% by mass aqueous solution at 20° C. is 2.0 to 50.0 mPa·s and pullulan can be dissolved in the solvent.
2.固形製剤
次に、固形製剤について説明する。
固形製剤は、活性成分を少なくとも含む芯部と、前記芯部を前記フィルムコーティング用組成物により被覆した被覆部とを少なくとも有する。
活性成分としては、経口投与可能な活性成分であれば特に限定されるものではないが、医薬品に用いられる薬物、並びに栄養機能食品、特定保健用食品及び機能性表示食品等の健康食品に用いられる活性成分等が挙げられる。また、芯部は活性成分を少なくとも含む充填物が充填されたカプセル製剤であってもよい。
2. Solid Preparation Next, solid preparations will be explained.
The solid preparation has at least a core portion containing at least an active ingredient, and a coating portion in which the core portion is coated with the film coating composition.
The active ingredient is not particularly limited as long as it is an orally administrable active ingredient, but it is used in drugs used in pharmaceuticals, and health foods such as foods with nutritional function claims, foods for specified health uses, and foods with functional claims. Examples include active ingredients. Alternatively, the core may be a capsule preparation filled with a filler containing at least an active ingredient.
医薬品に用いられる薬物の例としては、中枢神経系薬物、循環器系薬物、呼吸器系薬物、消化器系薬物、抗生物質、鎮咳・去たん剤、抗ヒスタミン剤、解熱鎮痛消炎剤、利尿剤、自律神経作用薬、抗マラリア剤、止潟剤、向精神剤並びにビタミン類及びその誘導体等が挙げられる。 Examples of drugs used in pharmaceuticals include central nervous system drugs, circulatory system drugs, respiratory drugs, digestive system drugs, antibiotics, antitussive and expectorant agents, antihistamines, antipyretic, analgesic, and antiinflammatory agents, diuretics, and antipyretic agents. Neuroactive drugs, antimalarial drugs, anti-lagogues, psychotropic drugs, vitamins and their derivatives, etc. can be mentioned.
中枢神経系薬物の例としては、ジアゼパム、イデベノン、ナプロキセン、ピロキシカム、インドメタシン、スリンダック、ロラゼパム、ニトラゼパム、フェニトイン、アセトアミノフェン、エテンザミド、ケトプロフェン及びクロルジアゼポキシド等が挙げられる。 Examples of central nervous system drugs include diazepam, idebenone, naproxen, piroxicam, indomethacin, sulindac, lorazepam, nitrazepam, phenytoin, acetaminophen, ethenzamide, ketoprofen, and chlordiazepoxide.
循環器系薬物の例としては、モルシドミン、ビンポセチン、プロプラノロール、メチルドパ、ジピリダモール、フロセミド、トリアムテレン、ニフェジビン、アテノロール、スピロノラクトン、メトプロロール、ピンドロール、カプトプリル、硝酸イソソルビト、塩酸デラプリル、塩酸メクロフェノキサート、塩酸ジルチアゼム、塩酸エチレフリン、ジギトキシン及び塩酸アルプレノロール等が挙げられる。 Examples of cardiovascular drugs include molsidomine, vinpocetine, propranolol, methyldopa, dipyridamole, furosemide, triamterene, nifedibine, atenolol, spironolactone, metoprolol, pindolol, captopril, isosorbitate nitrate, delapril hydrochloride, meclofenoxate hydrochloride, diltiazem hydrochloride, Examples include etilefrine hydrochloride, digitoxin, and alprenolol hydrochloride.
呼吸器系薬物の例としては、アムレキサノクス、デキストロメトルファン、テオフィリン、プソイドエフェドリン、サルブタモール及びグアイフェネシン等が挙げられる。 Examples of respiratory drugs include amlexanox, dextromethorphan, theophylline, pseudoephedrine, salbutamol, and guaifenesin.
消化器系薬物の例としては、2-[〔3-メチル-4-(2,2,2-トリフルオロエトキシ)-2-ピリジル〕メチルスルフィニル]ベンゾイミダゾール及び5-メトキシ-2-〔(4-メトキシ-3,5-ジメチル-2-ピリジル)メチルスルフィニル〕ベンゾイミダゾール等の抗潰瘍作用を有するベンゾイミダゾール系薬物、シメチジン、ラニチジン、塩酸ピレンゼピン、パンクレアチン、ビサコジル及び5-アミノサリチル酸等が挙げられる。 Examples of gastrointestinal drugs include 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methylsulfinyl]benzimidazole and 5-methoxy-2-[(4 -Methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl] Benzimidazole drugs with antiulcer effects such as benzimidazole, cimetidine, ranitidine, pirenzepine hydrochloride, pancreatin, bisacodyl, and 5-aminosalicylic acid, etc. .
抗生物質の例としては、塩酸タランピシリン、塩酸バカンピシリン、セファクロル及びエリスロマイシン等が挙げられる。 Examples of antibiotics include talampicillin hydrochloride, bacampicillin hydrochloride, cefaclor, and erythromycin.
鎮咳・去たん剤の例としては、塩酸ノスカピン、クエン酸カルベタペンタン、クエン酸イソアミニル及びリン酸ジメモルファン等が挙げられる。 Examples of antitussive and expectorant agents include noscapine hydrochloride, carbetapentane citrate, isoaminyl citrate, and dimemorphan phosphate.
抗ヒスタミン剤の例としては、マレイン酸クロルフェニラミン、塩酸ジフェンヒドラミン及び塩酸プロメタジン等が挙げられる。 Examples of antihistamines include chlorpheniramine maleate, diphenhydramine hydrochloride, and promethazine hydrochloride.
解熱鎮痛消炎剤の例としては、イブプロフェン、ジクロフェナクナトリウム、フルフェナム酸、スルピリン、アスピリン及びケトプロフェン等が挙げられる。 Examples of antipyretic, analgesic, and antiinflammatory agents include ibuprofen, diclofenac sodium, flufenamic acid, sulpirin, aspirin, and ketoprofen.
利尿剤の例としては、カフェイン等が挙げられる。 Examples of diuretics include caffeine and the like.
自律神経作用薬の例としては、リン酸ジヒドロコデイン、dl-塩酸メチルエフェドリン、硫酸アトロピン、塩化アセチルコリン及びネオスチグミン等が挙げられる。 Examples of autonomic nerve agents include dihydrocodeine phosphate, dl-methylephedrine hydrochloride, atropine sulfate, acetylcholine chloride, neostigmine, and the like.
抗マラリア剤の例としては、塩酸キニーネ等が挙げられる。 Examples of antimalarials include quinine hydrochloride and the like.
止潟剤の例としては、塩酸ロペラミド等が挙げられる。 Examples of anti-lagogues include loperamide hydrochloride and the like.
向精神剤の例としては、クロルプロマジン等が挙げられる。 Examples of psychotropic agents include chlorpromazine and the like.
ビタミン類及びその誘導体の例としては、ビタミンA、ビタミンB1、フルスルチアミン、ビタミンB2、ビタミンB6、ビタミンB12、ビタミンC、ビタミンD、ビタミンE、ビタミンK及びパントテン酸カルシウム等が挙げられる。 Examples of vitamins and derivatives thereof include vitamin A, vitamin B1, fursultiamine, vitamin B2, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, and calcium pantothenate.
健康食品に用いられる活性成分の例としては、前記ビタミン類及びその誘導体、ミネラル、カロテノイド、アミノ酸及びその誘導体、植物エキス並びに健康食品素材等が挙げられる。 Examples of active ingredients used in health foods include the aforementioned vitamins and their derivatives, minerals, carotenoids, amino acids and their derivatives, plant extracts, and health food materials.
ミネラルの例としては、カルシウム、マグネシウム、マンガン、亜鉛、鉄、銅、セレン、クロム、硫黄及びヨウ素等が挙げられる。 Examples of minerals include calcium, magnesium, manganese, zinc, iron, copper, selenium, chromium, sulfur, and iodine.
カロテノイドの例としては、β-カロテン、α-カロテン、ルテイン、クリプトキサンチン、ゼアキサンチン、リコペン、アスタキサンチン及びマルチカロテン等が挙げられる。 Examples of carotenoids include β-carotene, α-carotene, lutein, cryptoxanthin, zeaxanthin, lycopene, astaxanthin, multicarotene, and the like.
アミノ酸の例としては、酸性アミノ酸、塩基性アミノ酸、中性アミノ酸及び酸性アミノ酸アミド等が挙げられる。
酸性アミノ酸の例としては、アスパラギン酸及びグルタミン酸等が挙げられる。
塩基性アミノ酸の例としては、リシン、アルギニン及びヒスチジン等が挙げられる。
中性アミノ酸の例としては、アラニン及びグリシン等の直鎖状の脂肪族アミノ酸、バリン、ロイシン及びイソロイシン等の分岐状の脂肪族アミノ酸、セリン及びトレオニン等のヒドロキシアミノ酸、システイン及びメチオニン等の含硫アミノ酸、フェニルアラニン及びチロシン等の芳香族アミノ酸、トリプトファン等の複素環式アミノ酸並びにプロリン等のイミノ酸、トラネキサム酸等の非天然アミノ酸等が挙げられる。
酸性アミノ酸アミドの例としては、アスパラギン及びグルタミン等が挙げられる。
アミノ酸誘導体の例としては、アセチルグルタミン、アセチルシステイン、カルボキシメチルシステイン、アセチルチロシン、アセチルヒドロキシプロリン、5-ヒドロキシプロリン、グルタチオン、クレアチン、S-アデノシルメチオニン、グリシルグリシン、グリシルグルタミン、ドーパ、アラニルグルタミン、カルニチン及びγ-アミノ酪酸等が挙げられる。
Examples of amino acids include acidic amino acids, basic amino acids, neutral amino acids, and acidic amino acid amides.
Examples of acidic amino acids include aspartic acid and glutamic acid.
Examples of basic amino acids include lysine, arginine, histidine, and the like.
Examples of neutral amino acids include linear aliphatic amino acids such as alanine and glycine, branched aliphatic amino acids such as valine, leucine and isoleucine, hydroxy amino acids such as serine and threonine, and sulfur-containing amino acids such as cysteine and methionine. Examples include amino acids, aromatic amino acids such as phenylalanine and tyrosine, heterocyclic amino acids such as tryptophan, imino acids such as proline, and unnatural amino acids such as tranexamic acid.
Examples of acidic amino acid amides include asparagine and glutamine.
Examples of amino acid derivatives include acetylglutamine, acetylcysteine, carboxymethylcysteine, acetyltyrosine, acetylhydroxyproline, 5-hydroxyproline, glutathione, creatine, S-adenosylmethionine, glycylglycine, glycylglutamine, dopa, ara Examples include nylglutamine, carnitine, and γ-aminobutyric acid.
植物エキスの例としては、アロエ、プロポリス、アガリクス、高麗人参、イチョウ葉、ウコン、クルクミン、発芽玄米、椎茸菌糸体、甜茶、甘茶、メシマコブ、ごま、にんにく、マカ、冬虫夏草、カミツレ及びトウガラシ等の各エキスが挙げられる。 Examples of plant extracts include aloe, propolis, agaricus, ginseng, ginkgo biloba, turmeric, curcumin, germinated brown rice, shiitake mycelium, sweet tea, sweet tea, meshimakobu, sesame, garlic, maca, cordyceps sinensis, chamomile, and capsicum. Examples include extracts.
健康食品素材の例としては、ローヤルゼリー、食物繊維、プロテイン、ビフィズス菌、乳酸菌、キトサン、酵母、グルコサミン、レシチン、ポリフェノール、動物魚介軟骨、スッポン、ラクトフェリン、シジミ、エイコサペンタエン酸、ゲルマニウム、酵素、クレアチン、カルニチン、クエン酸、ラズベリーケトン、コエンザイムQ10、メチルスルホニルメタン及びリン脂質結合大豆ペプチド等が挙げられる。 Examples of health food ingredients include royal jelly, dietary fiber, protein, bifidobacteria, lactic acid bacteria, chitosan, yeast, glucosamine, lecithin, polyphenols, animal cartilage, soft-shelled turtle, lactoferrin, freshwater clam, eicosapentaenoic acid, germanium, enzymes, creatine, Examples include carnitine, citric acid, raspberry ketone, coenzyme Q10, methylsulfonylmethane, and phospholipid-bound soybean peptide.
活性成分の使用量は、製剤の種類に応じて適宜決定することができる。活性成分は、必要に応じて2種類以上を併用してもよい。また、活性成分は、市販のものを用いることができる。 The amount of active ingredient to be used can be appropriately determined depending on the type of formulation. Two or more types of active ingredients may be used in combination as necessary. Furthermore, commercially available active ingredients can be used.
活性成分を少なくとも含む芯部には、賦形剤、結合剤、崩壊剤、滑択剤(凝集防止剤)、流動化剤、着色剤及び医薬化合物の溶解補助剤等から選択される1種以上の添加剤を配合してもよい。 The core portion containing at least the active ingredient contains one or more selected from excipients, binders, disintegrants, lubricants (anti-aggregation agents), flow agents, colorants, solubilizing agents for pharmaceutical compounds, etc. Additives may also be added.
賦形剤の例としては、白糖、乳糖、マンニトール、グルコース等の糖類、でんぷん、結晶セルロース、リン酸カルシウム及び硫酸カルシウム等が挙げられる。 Examples of excipients include sugars such as white sugar, lactose, mannitol, and glucose, starch, crystalline cellulose, calcium phosphate, and calcium sulfate.
結合剤の例としては、ポリビニルアルコール、ポリアクリル酸、ポリメタクリル酸、ポリビニルピロリドン、グルコース、白糖、乳糖、麦芽糖、デキストリン、ソルビトール、マンニトール、ヒドロキシエチルセルロース、ヒドロキシプロピルメチルセルロース、ヒドロキシプロピルセルロース、マクロゴール類(例えば、マクロゴール4000、マクロゴール6000、マクロゴール20000等)、アラビアゴム、ゼラチン、寒天及びでんぷん(コーンスターチ等)等が挙げられる。 Examples of binders include polyvinyl alcohol, polyacrylic acid, polymethacrylic acid, polyvinylpyrrolidone, glucose, sucrose, lactose, maltose, dextrin, sorbitol, mannitol, hydroxyethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, macrogol ( Examples include macrogol 4000, macrogol 6000, macrogol 20000, etc.), gum arabic, gelatin, agar, and starch (cornstarch, etc.).
崩壊剤の例としては、低置換度ヒドロキシプロピルセルロース、カルメロース又はその塩、クロスカルメロースナトリウム、カルボキシメチルスターチナトリウム、クロスポリビニルピロリドン、結晶セルロース及び結晶セルロース・カルメロースナトリウム等が挙げられる。 Examples of disintegrants include low-substituted hydroxypropylcellulose, carmellose or its salts, croscarmellose sodium, sodium carboxymethyl starch, crospolyvinylpyrrolidone, crystalline cellulose, and crystalline cellulose/carmellose sodium.
滑択剤(凝集防止剤)の例としては、タルク、ステアリン酸マグネシウム、ステアリン酸カルシウム、コロイダルシリカ、ステアリン酸、ワックス類、硬化油、ポリエチレングリコール類及び安息香酸ナトリウム等が挙げられる。 Examples of lubricants (anti-aggregation agents) include talc, magnesium stearate, calcium stearate, colloidal silica, stearic acid, waxes, hydrogenated oils, polyethylene glycols, and sodium benzoate.
流動化剤としては、含水二酸化ケイ素、軽質無水ケイ酸及び酸化チタン等が挙げられる。 Examples of the fluidizing agent include hydrated silicon dioxide, light anhydrous silicic acid, and titanium oxide.
着色剤の例としては、黄色三二酸化鉄、三二酸化鉄、食用青色1号、食用青色2号、食用黄色4号、食用黄色5号、食用緑色3号、食用赤色2号、食用赤色3号、食用赤色102号、食用赤色104号、食用赤色105号及び食用赤色106号等が挙げられる。 Examples of colorants include yellow iron sesquioxide, iron sesquioxide, food blue No. 1, food blue No. 2, food yellow No. 4, food yellow No. 5, food green No. 3, food red No. 2, and food red No. 3. , Food Red No. 102, Food Red No. 104, Food Red No. 105, Food Red No. 106, and the like.
医薬化合物の溶解補助剤の例としては、フマル酸、コハク酸、リンゴ酸及びアジピン酸等の有機酸等が挙げられる。 Examples of solubilizing agents for pharmaceutical compounds include organic acids such as fumaric acid, succinic acid, malic acid, and adipic acid.
添加剤の使用量は、製剤の種類等に応じて適宜決定することができる。添加剤は、必要に応じて2種類以上を併用してもよい。また、添加剤は、市販のものを用いることができる。 The amount of the additive to be used can be determined as appropriate depending on the type of formulation and the like. Two or more types of additives may be used in combination as necessary. Moreover, commercially available additives can be used.
活性成分を少なくとも含む芯部の形状(剤形)は、特に限定されず、錠剤、散剤、顆粒剤、細粒剤、丸剤、トローチ剤、カプセル剤等が挙げられるが、その中でも特に錠剤が好ましい。
錠剤の例としては、素錠、糖衣錠、ゼラチン被包錠、フィルムコーティング錠(多層フィルムコーティング錠を含む)、腸溶性コーティング錠及び有核錠(圧縮被包錠)等が挙げられる。
また、活性成分を少なくとも含む芯部には、必要に応じて、フィルムコーティング用組成物をコーティングする前に、ヒドロキシプロピルメチルセルロース等のコーティング基剤を用いて、アンダーコーティングの処理を行ってもよい。
The shape (dosage form) of the core containing at least the active ingredient is not particularly limited, and examples include tablets, powders, granules, fine granules, pills, troches, and capsules, among which tablets are particularly preferred. preferable.
Examples of tablets include plain tablets, sugar-coated tablets, gelatin-coated tablets, film-coated tablets (including multilayer film-coated tablets), enteric-coated tablets, and dry-coated tablets (compressed tablets).
Furthermore, if necessary, the core portion containing at least the active ingredient may be subjected to undercoating treatment using a coating base such as hydroxypropyl methyl cellulose before being coated with the film coating composition.
活性成分を少なくとも含む芯部の表面に被覆されるフィルムコーティング用組成物の被覆量は、製剤の種類、形、大きさ、表面状態、製剤中に含まれる薬物及び添加剤の性質等に応じて適宜決定することができる。例えば、活性成分を少なくとも含む芯部の形状(剤形)が錠剤である場合においては、芯部100質量部に対して、被覆量の均一性の観点から、フィルムコーティング用組成物の固形分の量は、好ましくは0.5~15質量%であり、より好ましくは5~10質量%である。なお、前記フィルムコーティング用組成物の「固形分の量」とは、フィルムコーティング用組成物の溶媒を除く成分の合計量、すなわち、非イオン性水溶性セルロースエーテル及びプルランの合計量であり、必要に応じての添加剤を含む場合は、該添加剤の含有量も加えた量である。 The amount of film coating composition coated on the surface of the core containing at least the active ingredient depends on the type, shape, size, surface condition of the preparation, properties of the drug and additives contained in the preparation, etc. It can be determined as appropriate. For example, when the shape (dosage form) of the core containing at least the active ingredient is a tablet, the solid content of the film coating composition is The amount is preferably 0.5-15% by weight, more preferably 5-10% by weight. The "solid content" of the film coating composition is the total amount of the components of the film coating composition excluding the solvent, that is, the total amount of nonionic water-soluble cellulose ether and pullulan. When containing additives according to the above, the amount includes the content of the additives.
また、錠剤における被覆部の厚みは、均一な連続被膜(層)の形成の観点から、好ましくは20~30μmである。錠剤における被覆部の厚みは、デジタルマイクロスコープVHX-2000(株式会社キーエンス)を用いて測定することができる。 Further, the thickness of the coating portion of the tablet is preferably 20 to 30 μm from the viewpoint of forming a uniform continuous film (layer). The thickness of the coating in the tablet can be measured using a digital microscope VHX-2000 (Keyence Corporation).
3.固形製剤の製造方法
固形製剤の製造方法について説明する。
固形製剤は、前記フィルムコーティング用組成物を、活性成分を少なくとも含む芯部にコーティング装置を用いて被覆して被覆部を形成する工程と、乾燥して前記溶媒を除去する工程とを少なくとも含む製造方法により得られる。コーティング装置の例としては、パンコーティング装置、ドラムタイプコーティング装置、流動層コーティング装置及び攪拌流動コーティング装置等が挙げられる。コーティング装置としては、従来公知のものを使用できる。また、コーティング装置に付帯するスプレー装置の例としては、エアースプレーエアレススプレー及び3流体スプレー等が挙げられる。
被覆する方法としては特に限定されないが、例えば、フィルムコーティング用組成物を、活性成分を少なくとも含む芯部に塗布する方法が挙げられる。
乾燥して溶媒を除去する工程では、公知の乾燥方法、例えば自然乾燥、棚段乾燥機を用いた乾燥方法、通気乾燥方式のコーティング装置を用いた乾燥方法が挙げられる。
3. Method for manufacturing solid preparations The method for manufacturing solid preparations will be explained.
The solid preparation includes at least the steps of: coating a core containing at least the active ingredient with the film coating composition using a coating device to form a coating; and drying to remove the solvent. obtained by the method. Examples of coating equipment include pan coating equipment, drum type coating equipment, fluidized bed coating equipment, and agitated fluidized coating equipment. As the coating device, conventionally known devices can be used. Further, examples of spray devices attached to the coating device include an air spray, an airless spray, and a three-fluid spray.
The coating method is not particularly limited, but includes, for example, a method of applying a film coating composition to the core portion containing at least the active ingredient.
In the step of drying to remove the solvent, known drying methods include natural drying, a drying method using a tray dryer, and a drying method using a ventilation drying type coating device.
上述のようにして、活性成分を少なくとも含む芯部と前述のフィルムコーティング用組成物を被覆することにより形成された被覆部とを少なくとも備える固形製剤を製造することができる。前述のフィルムコーティング用組成物により形成された被覆部は、溶媒等の揮発成分が除去されるため、20℃における2質量%水溶液の粘度が2.0~50.0mPa・sである非イオン性水溶性セルロースエーテルとプルランとを少なくとも含み、前記非イオン性水溶性セルロースエーテルと前記プルランとの質量比が80:20~55:45である被覆部となる。前記被覆部は水分子を通しにくく、水蒸気バリア性に優れることから防湿性に優れている。この防湿性により、水分の影響を受けやすい活性成分を含む芯部を保護することができ、結果として分解物が発生しづらくなるとともに、分解の有無にかかわらず、活性成分から発される臭気成分も前記被覆部の壁により閉じ込めることができ、防臭性の効果へとつながる。
固形製剤の具体例としては、例えば、活性成分を少なくとも含む前記形状の芯部と、前記芯部の上の被覆部とを少なくとも備える製剤が挙げられる。また、前記フィルムコーティング用組成物は、フィルムコーティング用途の他にカプセル用途にも使用できる。
As described above, a solid preparation comprising at least a core portion containing at least an active ingredient and a coating portion formed by coating the above-described film coating composition can be produced. Since volatile components such as solvents are removed from the coating formed by the above-mentioned film coating composition, the coating is nonionic and has a viscosity of 2.0 to 50.0 mPa·s as a 2% by mass aqueous solution at 20°C. The coating portion contains at least water-soluble cellulose ether and pullulan, and the mass ratio of the nonionic water-soluble cellulose ether to the pullulan is 80:20 to 55:45. The coating portion is difficult to pass water molecules and has excellent water vapor barrier properties, so it has excellent moisture resistance. This moisture-proof property protects the core containing active ingredients that are susceptible to moisture, making it difficult for decomposition products to occur, and odor components emitted from active ingredients regardless of whether they are decomposed or not. can also be trapped by the wall of the coating, leading to an odor-proofing effect.
Specific examples of solid preparations include, for example, preparations that include at least a core portion having the above-mentioned shape and containing an active ingredient, and a coating portion on the core portion. Furthermore, the film coating composition can be used not only for film coating purposes but also for capsule purposes.
以下に、実施例及び比較例を示し、本発明を具体的に説明するが、本発明はこれらの実施例に限定されるものではない。 EXAMPLES Below, the present invention will be specifically explained with reference to Examples and Comparative Examples, but the present invention is not limited to these Examples.
実施例1
プルラン(株式会社林原製 商品名『食品添加物プルラン』))20gを、900gの精製水に撹拌機(ラボスターラ(LT-400D)、ヤマト科学社製)を用いて25℃、560rpmで15分間撹拌することにより溶解してプルランの水溶液を調製した。
調製したプルランの水溶液を撹拌機(ラボスターラ(LT-400D)、ヤマト科学社製)を用いて80℃、560rpmで撹拌しながら、HPMC(2質量%水溶液の20℃における粘度:5.91mPa・s、メトキシ基の含有量28.8質量%、ヒドロキシプロポキシ基の含有量8.8質量%)80gを添加し80℃、560rpmで3分間撹拌することにより水に分散した後、20℃、560rpmで15分間撹拌することによりHPMCを溶解して、フィルムコーティング用組成物を製造した。
得られたフィルムコーティング用組成物を用いて、下記の組成を有する素錠を芯部として、下記のコーティング条件の下、素錠100質量部に対して固形分(HPMC及びプルラン)で10質量部になるまで被覆した後、コーティング溶液(フィルムコーティング用組成物)の噴霧を行わずに30分間、同一装置内にて給気温度を50~60℃、パン回転数を18rpmとして乾燥を行うことにより、素錠上に被覆部を形成したフィルムコーティング錠剤(固形製剤)を製造した。
<素錠の組成>
アスピリン:50質量%(アスピリン、山本化学工業社製)
乳糖:50質量%(Pharmatose(登録商標) 200M、DFE Pharma社製)
ステアリン酸マグネシウム:1質量%(ステアリン酸マグネシウム、太平化学産業社製)
錠剤形状:直径8.0mm、曲率半径12.0mm、質量200mg/錠
<コーティング条件>
装置:通気式パンコーター(HICOATER FZ LABO、コーティングパンの内径30cm、フロイント産業社製)
素錠の仕込み量:1kg
給気温度:75~80℃
排気温度:44~49℃
吸気エアー量:0.45m3/min
パン回転数:18~24rpm
スプレー速度:5g/min
スプレーエアー圧:100kPa
ノズル径:1.0mm
Example 1
20 g of Pullulan (manufactured by Hayashibara Co., Ltd., trade name ``Food Additive Pullulan'') was stirred in 900 g of purified water at 25°C and 560 rpm for 15 minutes using a stirrer (Labo Stara (LT-400D), manufactured by Yamato Scientific Co., Ltd.). An aqueous solution of pullulan was prepared by dissolving it.
While stirring the prepared pullulan aqueous solution at 80°C and 560 rpm using a stirrer (Labo Stirra (LT-400D), manufactured by Yamato Scientific Co., Ltd.), HPMC (viscosity of 2% by mass aqueous solution at 20°C: 5.91 mPa・s , methoxy group content 28.8% by mass, hydroxypropoxy group content 8.8% by mass) was added and dispersed in water by stirring at 80°C and 560 rpm for 3 minutes, and then at 20°C and 560 rpm. The HPMC was dissolved by stirring for 15 minutes to prepare a film coating composition.
Using the obtained composition for film coating, using the core of an uncoated tablet having the following composition, under the following coating conditions, the solid content (HPMC and pullulan) was 10 parts by mass per 100 parts by mass of the uncoated tablet. After coating until the coating solution (film coating composition) was coated, drying was performed in the same device for 30 minutes without spraying the coating solution (film coating composition) at a supply air temperature of 50 to 60 ° C. and a pan rotation speed of 18 rpm. A film-coated tablet (solid preparation) in which a coating portion was formed on a plain tablet was manufactured.
<Composition of uncoated tablet>
Aspirin: 50% by mass (aspirin, manufactured by Yamamoto Chemical Industry Co., Ltd.)
Lactose: 50% by mass (Pharmatose (registered trademark) 200M, manufactured by DFE Pharma)
Magnesium stearate: 1% by mass (magnesium stearate, manufactured by Taihei Kagaku Sangyo Co., Ltd.)
Tablet shape: diameter 8.0 mm, radius of curvature 12.0 mm, mass 200 mg/tablet
<Coating conditions>
Equipment: Ventilated pan coater (HICOATER FZ LABO, inner diameter of coating pan 30 cm, manufactured by Freund Sangyo Co., Ltd.)
Amount of uncoated tablets: 1kg
Supply air temperature: 75-80℃
Exhaust temperature: 44-49℃
Intake air amount: 0.45m 3 /min
Pan rotation speed: 18-24 rpm
Spray speed: 5g/min
Spray air pressure: 100kPa
Nozzle diameter: 1.0mm
<コーティング時のノズル閉塞の発生の評価基準>
以下、各評価基準に基づき、「◎」は「良好」、「○」は「普通」、「×」は「不良」と判定した。
◎:ノズル閉塞の発生無し
○:スケールの発生が見られたがノズル閉塞の発生無し
×:ノズル閉塞の発生あり
<Evaluation criteria for occurrence of nozzle blockage during coating>
Below, based on each evaluation criterion, "◎" was determined to be "good,""○" was determined to be "fair," and "x" was determined to be "poor."
◎: No nozzle blockage occurred. ○: Scale formation was observed, but nozzle blockage did not occur. ×: Nozzle blockage occurred.
<コーティング錠剤の表面荒れの評価基準>
以下、各評価基準に基づき、「◎」は「良好」、「○」は「普通」、「×」は「不良」と判定した。表面荒れがない又は一部のみである場合、粘着性が改善できていることを示す。表面荒れは目視で確認した。
◎:表面荒れ無し
○:一部表面荒れ有り
×:表面荒れ有り
<Evaluation criteria for surface roughness of coated tablets>
Below, based on each evaluation criterion, "◎" was determined to be "good,""○" was determined to be "fair," and "x" was determined to be "poor." If there is no surface roughness or only some surface roughness, it indicates that the tackiness has been improved. Surface roughness was visually confirmed.
◎: No surface roughness ○: Some surface roughness ×: Surface roughness
<遊離酢酸の評価>
ヘッドスペースサンプラー専用バイアルにフィルムコーティング錠剤30錠を入れ、密栓した後12時間静置し、その後、ヘッドスペースサンプラーおよびガスクロマトグラフィーを用いて下記分析条件により、前記錠剤から発生した遊離酢酸を測定した。遊離酢酸が検出されない場合、防臭効果があることが示される。
[分析条件]
≪オートサンプラー(HS-20)≫
サンプルライン温度:150℃
トランスファーライン温度:150℃
バイアル加圧用ガス加圧:50kPa
注入時間:0.5min
カラム名称:SH-Stabilwax(液相膜厚0.5μm、長さ30m、内径0.32mmID)
検出器:FID1
検出器温度:250℃
メイクアップガス:He
メイクアップ流量:24mL/min
H2流量:30mL/min
Air流量:200mL/min
制御モード:線速度(40cm/sec)
<Evaluation of free acetic acid>
30 film-coated tablets were placed in a vial exclusively for the headspace sampler, and the vial was sealed and allowed to stand for 12 hours. Then, free acetic acid generated from the tablets was measured using a headspace sampler and gas chromatography under the following analysis conditions. . If free acetic acid is not detected, it indicates that there is a deodorizing effect.
[Analysis conditions]
≪Auto sampler (HS-20)≫
Sample line temperature: 150℃
Transfer line temperature: 150℃
Gas pressurization for vial pressurization: 50kPa
Injection time: 0.5min
Column name: SH-Stabilwax (liquid phase film thickness 0.5 μm, length 30 m, inner diameter 0.32 mm ID)
Detector: FID1
Detector temperature: 250℃
Make-up gas: He
Makeup flow rate: 24mL/min
H2 flow rate: 30mL/min
Air flow rate: 200mL/min
Control mode: linear velocity (40cm/sec)
実施例2~3並びに比較例1~4
フィルムコーティング用組成物の組成を表1に記載される組成に変更すること以外は、実施例1と同様にコーティング用組成物を製造し、素錠に対してコーティングを行い、ノズル閉塞の発生、コーティング錠剤の表面荒れ及び遊離酢酸の評価を行った。なお、実施例3では、フィルムコーティング用組成物に用いる非イオン性水溶性セルロースエーテルとして、MC(2質量%水溶液の20℃における粘度:4.04mPa・s、メトキシ基の含有量29.4質量%)を用いた。結果を表1に示す。
Examples 2-3 and Comparative Examples 1-4
A coating composition was produced in the same manner as in Example 1, except that the composition of the film coating composition was changed to the composition listed in Table 1, and uncoated tablets were coated to prevent nozzle clogging. The surface roughness and free acetic acid of the coated tablets were evaluated. In Example 3, as the nonionic water-soluble cellulose ether used in the film coating composition, MC (viscosity at 20°C of 2% by mass aqueous solution: 4.04 mPa·s, methoxy group content 29.4% by mass) %) was used. The results are shown in Table 1.
表1から明らかなように、本発明のフィルムコーティング錠剤は、防臭に十分な効果を示し、コーティング工程におけるスプレーノズルの閉塞が発生せず、錠剤同士の付着による錠剤表面の荒れがなかった。非イオン性水溶性セルロースエーテルとプルランを所定の割合にて用いることにより、防臭が可能となった。
一方、比較例1のコーティング錠剤は、一定濃度の遊離酢酸が検出され、防臭効果が十分ではなかった。また、比較例2では、コーティング中のノズル閉塞が発生し、さらに錠剤同士の付着による錠剤表面の荒れが発生しており、生産性にも劣るものであった。
As is clear from Table 1, the film-coated tablets of the present invention exhibited sufficient deodorizing effects, did not cause blockage of the spray nozzle during the coating process, and did not cause roughening of the tablet surface due to adhesion of tablets to each other. Odor control has become possible by using nonionic water-soluble cellulose ether and pullulan in a predetermined ratio.
On the other hand, in the coated tablet of Comparative Example 1, a certain concentration of free acetic acid was detected, and the deodorizing effect was not sufficient. Furthermore, in Comparative Example 2, nozzle clogging occurred during coating, and the tablet surface was roughened due to adhesion of tablets to each other, resulting in poor productivity.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022143774A JP2024039317A (en) | 2022-09-09 | 2022-09-09 | Composition for film coating, solid preparation, and method for producing solid preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022143774A JP2024039317A (en) | 2022-09-09 | 2022-09-09 | Composition for film coating, solid preparation, and method for producing solid preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2024039317A true JP2024039317A (en) | 2024-03-22 |
Family
ID=90326237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022143774A Pending JP2024039317A (en) | 2022-09-09 | 2022-09-09 | Composition for film coating, solid preparation, and method for producing solid preparation |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2024039317A (en) |
-
2022
- 2022-09-09 JP JP2022143774A patent/JP2024039317A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1459740B1 (en) | Compositions containing sucralose | |
CA2732093A1 (en) | Controlled release formulations using intelligent polymers | |
JP5667113B2 (en) | Composition for coating for time-release preparation, time-release solid preparation coated thereby, and method for producing time-release solid preparation | |
HUE034511T2 (en) | Solid dosage form containing a low viscosity HYDROXYALKYL CELLULOSE | |
JP6780412B2 (en) | Coating composition and coating formulation and method for manufacturing the same | |
CA3124534C (en) | Cellulose powder, use thereof, and tablets | |
JP5162141B2 (en) | Film coating composition | |
JP7165626B2 (en) | COATING COMPOSITION FOR TABLETS TO BE INKJET PRINTED, TABLETS PRINTED WITH WATER-BASED INK USING SAME, AND MANUFACTURING METHOD THEREOF | |
JP6924177B2 (en) | Pharmaceutical composition particles and orally disintegrating preparation containing them | |
US20080031927A1 (en) | Solid oral dosage vitamin and mineral compositions | |
JP2024039317A (en) | Composition for film coating, solid preparation, and method for producing solid preparation | |
JP7414668B2 (en) | Granules and solid preparations containing polyvinyl alcohol | |
JP2010189378A (en) | Film-coated sublimable component-containing solid preparation | |
JP2014221847A (en) | Sugar-coated preparation and method for producing the same | |
JP2024013563A (en) | Coating composition, solid preparation, and method for producing solid preparation | |
JP2020094022A (en) | Excipient granules, tablet and method for producing tablet | |
WO2022014601A1 (en) | Film-coated tablets | |
US10980747B2 (en) | Composition for solid preparation, solid preparation, and method for producing the same | |
JP6983139B2 (en) | Compositions for solid formulations, solid formulations and methods for producing them | |
JP2023184503A (en) | liquid composition | |
KR102011512B1 (en) | Film coating composition and oral solid preparation | |
JP2021031404A (en) | Composition for orally disintegrating tablet and production method thereof as well as orally disintegrating tablet using the same and production method thereof | |
JP5819800B2 (en) | Coating liquid in which high-viscosity hypromellose is dispersed and method for producing solid preparation | |
JP2021070663A (en) | Coating composition, coated solid preparation, method for producing coated solid preparation, and coating method | |
JP2020094023A (en) | Excipient granules, tablet and method for producing tablet |